Somewhat Critical News Coverage Somewhat Likely to Affect Oxford Immunotec Global PLC (OXFD) Stock Price

News articles about Oxford Immunotec Global PLC (NASDAQ:OXFD) have trended somewhat negative this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Oxford Immunotec Global PLC earned a news impact score of -0.20 on Accern’s scale. Accern also gave headlines about the company an impact score of 60 out of 100, indicating that recent press coverage is somewhat likely to have an impact on the company’s share price in the next few days.

These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

Insider Buying and Selling by Quarter for Oxford Immunotec Global PLC (NASDAQ:OXFD)

A number of analysts have commented on the company. ValuEngine upgraded Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. BTIG Research reiterated a “buy” rating on shares of Oxford Immunotec Global PLC in a research report on Thursday, May 4th. Finally, Zacks Investment Research downgraded Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a research report on Wednesday, May 3rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $18.00.

Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) opened at 15.34 on Friday. The company’s market cap is $351.68 million. The firm has a 50 day moving average price of $14.45 and a 200-day moving average price of $14.57. Oxford Immunotec Global PLC has a 12 month low of $7.73 and a 12 month high of $16.13.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its quarterly earnings data on Tuesday, May 2nd. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.01. Oxford Immunotec Global PLC had a negative return on equity of 31.48% and a negative net margin of 25.83%. The firm had revenue of $21.51 million for the quarter, compared to the consensus estimate of $21.17 million. Analysts anticipate that Oxford Immunotec Global PLC will post ($1.06) earnings per share for the current fiscal year.

In other news, CEO Peter Wrighton-Smith sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, April 3rd. The stock was sold at an average price of $15.43, for a total transaction of $462,900.00. Following the completion of the sale, the chief executive officer now owns 491,668 shares in the company, valued at $7,586,437.24. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, April 3rd. The stock was sold at an average price of $15.47, for a total value of $46,410.00. Following the sale, the director now owns 17,174 shares of the company’s stock, valued at approximately $265,681.78. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 90,085 shares of company stock valued at $1,326,026. Corporate insiders own 7.58% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by sleekmoney and is the sole property of of sleekmoney. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://sleekmoney.com/somewhat-critical-news-coverage-somewhat-likely-to-affect-oxford-immunotec-global-plc-oxfd-stock-price/1933610.html.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/somewhat-critical-news-coverage-somewhat-likely-to-affect-oxford-immunotec-global-plc-oxfd-stock-price/1933610.html

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *